A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China

A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China

This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China.

Study Overview

• Status: Active, not recruiting
• Conditions: SARS-CoV-2
• Intervention / Treatment: Drug: Placebo; Biological: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose; Biological: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose

• Study Type: Interventional
• Enrollment (Actual): 54
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Anhui
    • Bengbu, Anhui, China
      • First Affiliated Hospital Bengbu Medical College

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age at the time of first dose of vaccine: adults aged 18-59 years (including boundary values), elderly ≥60 years, both sexes;
• Armpit temperature <37.3℃ on the day of enrollment;
• Based on the medical history and relevant physical examination and laboratory examination results, the investigator clinically determined that the patient was in good health;
• Subjects have independent judgment ability, can read, understand and complete vaccination diary cards, and they participate voluntarily and sign an informed consent form.

Exclusion Criteria:

• The subject has a history of SARS-CoV-2 or SARS infection, or has a history of contact with SARS-CoV-2 infected persons (nucleic acid test positive) or suspected infected persons within 30 days before screening, or living abroad within 30 days before screening history, or a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 IgM or IgG test before the first dose of vaccine;
• History of allergy to any component of the study vaccine or a history of a severe allergic reaction to the vaccine or drug (including but not limited to anaphylactic shock, anaphylactic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, or local anaphylactic necrosis [Arthus reaction]);
• Upon questioning, have a history of COVID-19 vaccination, or have received other inactivated vaccines within 14 days before screening, and received live attenuated vaccines within 28 days;
• Patients have a medical history or family history of epilepsy, convulsions, neurological diseases and mental diseases;
• There are contraindications for intramuscular injection, such as: thrombocytopenia that has been diagnosed, any coagulation disorder or receiving anticoagulant treatment, etc.;
• The investigator judges that he is known or suspected of having more serious diseases at the same time, including but not limited to: respiratory diseases (tuberculosis, lung failure, etc.), liver and kidney diseases, cardiovascular diseases (heart failure, severe hypertension, etc.), Malignant tumor, infection or allergic skin disease, HIV infection (test report can be provided), or during the active period of acute infection or chronic disease (within 3 days before vaccination);
• Congenital malformations, developmental disorders, or chronic diseases that the investigator judges are not suitable for participating in this study (such as Downs syndrome, sickle cell anemia or neurological disorders, Guillain-Barre syndrome, etc.), excluding stable diabetes/hypertension );
• Patients with known immunological impairment or low immunological function diagnosed by the hospital before enrollment, or functional asplenia or splenectomy caused by any situation;
• Those with evidence of tobacco, alcohol, and drug abuse, and those who did not agree to abstain from smoking and drinking during the study period;
• During the screening period, laboratory tests (blood routine, urine routine, blood biochemistry, troponin, coagulation routine, D-dimer) and electrocardiogram abnormalities were clinically significant;
• Female: those who have a positive blood pregnancy test, are pregnant, breastfeeding, or have a pregnancy plan within one year; men: whose spouse has a pregnancy plan within one year;
• Patients have participated in other clinical trials (drugs, biological products or devices) within 3 months before the first dose of vaccine, or plan to participate in other clinical trials during the research period;
• Patients received immune enhancement or immunosuppressive therapy within 6 months before the first dose of vaccine (continuous oral or instillation for more than 14 days);
• Patients donated blood ≥400 ml within 28 days before screening, or received whole blood, plasma and immunoglobulin therapy within 6 months before screening;
• Currently receiving research drug treatment to prevent COVID-19;
• Patients are taking antipyretic, analgesic and anti-allergic drugs within 3 days before enrollment;
• The investigator judges that the subjects cannot follow the research procedures, comply with the agreement, or plan to permanently relocate from the area before the end of the research, or plan to leave the local area for a long time during the scheduled visit period;
• The relevant staff involved in this study or their immediate family members (such as spouses, parents, siblings or children);
• According to the investigator's judgment, there are other situations that are not suitable for participating in this clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 50μg; Two doses were administered by intramuscular injection, 28 days apart	Drug: Placebo; Saline solution; Biological: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose; 50μg/dose
EXPERIMENTAL: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 100μg; Two doses were administered by intramuscular injection, 28 days apart	Drug: Placebo; Saline solution; Biological: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose; 100μg/dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of solicited adverse events	Within 28 days after each dose/full dose
Incidence of unsolicited adverse events	Within 28 days after each dose/full dose
Incidence of adverse events associated with the study vaccine	Within 28 days after each dose/full dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of SAE		Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Incidence of AESI		Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Incidence of SAE associated with the study vaccine		Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Incidence of AESI associated with the study vaccine		Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
Incidence of grade ≥3 adverse events	Adverse events were graded from pain, tenderness, itching, induration, swelling and other aspects, and the higher the grade, the more serious the adverse events were	Within 28 days after each dose/full dose
Incidence of grade ≥3 adverse events associated with the study vaccine	Adverse events were graded from pain, tenderness, itching, induration, swelling and other aspects, and the higher the grade, the more serious the adverse events were	Within 28 days after each dose/full dose
Statistics of withdrawal from the study due to adverse events		Within 28 days after each dose/full dose
Incidence of clinically significant abnormalities in laboratory measures		Through study completion, an average of 12 months

Other Outcome Measures

Outcome Measure	Time Frame
The positive conversion rate of S-protein specific antibody (IgG) against Novel coronavirus 2019	14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
The geometric mean titers (GMT) of S protein-specific antibody (IgG) against Novel coronavirus 2019	14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
The average growth fold compared with the baseline before exemption of S protein-specific antibody (IgG) against Novel coronavirus 2019	14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
The positive conversion rate of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus neutralizing antibodies	14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
The positive conversion rate of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus neutralizing antibodies	14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
The geometric mean titers (GMT) of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus neutralizing antibodies	14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
The average growth fold compared with the baseline before exemption of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus neutralizing antibodies	14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
The geometric mean titers (GMT) of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus neutralizing antibodies	14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
The average growth fold compared with the baseline before exemption of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus neutralizing antibodies	14 and 28 days after the first dose and 7, 14, 28 days, and 3, 6, and 12 months after the full course of vaccination
Cellular immune responses against Novel Coronavirus 2019 (IL-2)	14, 28 days after the first dose and 7, 14, and 28 days after complete vaccination
Cellular immune responses against Novel Coronavirus 2019 (IL-4)	14, 28 days after the first dose and 7, 14, and 28 days after complete vaccination
Cellular immune responses against Novel Coronavirus 2019 (IL-13)	14, 28 days after the first dose and 7, 14, and 28 days after complete vaccination
Cellular immune responses against Novel Coronavirus 2019 (IL-γ)	14, 28 days after the first dose and 7, 14, and 28 days after complete vaccination

Collaborators and Investigators

• Sponsor: AIM Vaccine Co., Ltd.
• Collaborators: First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical Co. Ltd.

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 16, 2022
• Primary Completion (ACTUAL): December 19, 2022
• Study Completion (ANTICIPATED): March 1, 2024

Study Registration Dates

• First Submitted: September 18, 2022
• First Submitted That Met QC Criteria: September 20, 2022
• First Posted (ACTUAL): September 22, 2022

Study Record Updates

• Last Update Posted (ESTIMATE): February 14, 2023
• Last Update Submitted That Met QC Criteria: February 12, 2023
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: LVRNA012-IIT-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No